Journal of Viral Hepatitis最新文献

{"title":"Unhealthy Behaviours and All-Cause Mortality Among People With Chronic Hepatitis B, With and Without Hepatitis Delta (ANRS CO22 HEPATHER)","authors":"Clémence Ramier,&nbsp;Fabrice Carrat,&nbsp;Vincent Di Beo,&nbsp;Lucia Parlati,&nbsp;Marta Lotto,&nbsp;Fabienne Marcellin,&nbsp;Camelia Protopopescu,&nbsp;Patrizia Carrieri,&nbsp;Marc Bourliere,&nbsp;the ANRS/AFEF HEPATHER study group","doi":"10.1111/jvh.70033","DOIUrl":"https://doi.org/10.1111/jvh.70033","url":null,"abstract":"<p>People infected with both hepatitis B virus (HBV) and hepatitis Delta virus (HDV) face a higher mortality risk than those mono-infected with HBV. As unhealthy behaviours can influence liver disease progression, we compared the effects of various behavioural factors on all-cause mortality among people with chronic hepatitis B (CHB), with or without chronic hepatitis Delta (CHD). We used 5-year follow-up data from people with CHB participating in the French ANRS CO22 HEPATHER cohort. A Cox proportional hazards model helped determine whether the pattern of risk factors for all-cause mortality differed according to CHD status. Of the 3884 people included, 183 had CHD and 154 died during follow-up. After multivariable adjustment, daily soft drink consumption significantly increased mortality risk in people with CHD and almost reached significance in those without CHD (adjusted hazard ratio (aHR) [95% CI]: 6.09 [2.40–15.48], <i>p</i> &lt; 0.001, and 1.58 [0.97–2.56], <i>p</i> = 0.066 respectively). Moreover, past or current unhealthy alcohol use and tobacco smoking were both associated with a higher risk of mortality in all people with CHB (1.74 [1.09–2.79], <i>p</i> = 0.020, and 1.61 [1.13–2.31], <i>p</i> = 0.009 respectively). Daily soft drink consumption significantly increased all-cause mortality in people with CHD. Unhealthy alcohol use and tobacco smoking were associated with a higher mortality risk in all people with CHB. Education about healthy eating and support for smoking cessation and alcohol reduction could greatly improve health and survival of people with CHB, with and without CHD.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 7","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144179370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leading Role of Sofosbuvir/Daclatasvir in Achieving Hepatitis C Elimination in Egypt","authors":"Tamer Elbaz,&nbsp;Khalid Al-Naamani,&nbsp;Hazem Abosheaishaa,&nbsp;Khalid Alswat,&nbsp;Mohamed El-Kassas","doi":"10.1111/jvh.70032","DOIUrl":"https://doi.org/10.1111/jvh.70032","url":null,"abstract":"<div>\u0000 \u0000 <p>Chronic hepatitis C virus (HCV) management has historically been challenging, particularly in Egypt, the country with the highest global disease prevalence. The introduction of direct-acting antivirals (DAAs) has revolutionised treatment, providing high rates of sustained virologic response (SVR) with fewer adverse events compared to previous therapies. In Egypt, the locally produced generics of sofosbuvir/daclatasvir (SOF/DAC) have been integral to the national HCV elimination programme, treating millions effectively and affordably, demonstrating similar efficacy and safety to brand-name drugs. Although not currently present in most international guidelines, this cost-effective regimen offers a viable option for large-scale elimination programmes similar to Egypt's successful experience. This review synthesises real-world Egyptian data and highlights the efficacy and safety of the SOF/DAC combination in various population groups. High sustained virological response (SVR) rates were observed across diverse patient populations, including those with advanced liver disease. However, limitations regarding long-term follow-up, especially HCC surveillance, were identified, underscoring the need for further research. Additionally, the review underscores the success of local Egyptian pharmaceutical policies in reducing treatment costs and securing access for all infected individuals. The Egyptian experience offers valuable insights into the potential for replicating its success, particularly in other high-burden regions.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 7","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing Treatment Uptake for Chronic Hepatitis B in South America: A Comparative Analysis of Country-Specific and WHO 2024 Guidelines","authors":"Manuel Mendizabal,&nbsp;Constanza D. Sabate,&nbsp;Esteban González Ballerga,&nbsp;Fernando Gruz,&nbsp;Ezequiel Ridruejo,&nbsp;Alejandro Soza,&nbsp;Jaime Poniachik,&nbsp;Grace Vergara,&nbsp;Victoria Mainardi,&nbsp;Gabriel Mezzano,&nbsp;Fernando Bessone,&nbsp;Margarita Anders,&nbsp;Mario G. Pessoa,&nbsp;Fernando Cairo,&nbsp;Daniela Chiodi,&nbsp;Melisa Dirchwolf,&nbsp;Hugo Cheinquer,&nbsp;Melina Susana,&nbsp;Luis Rondeau,&nbsp;Gabriel Rifrani,&nbsp;Herman Aguirre,&nbsp;Nelia Hernandez,&nbsp;Carla Enrique,&nbsp;Lucia Navarro,&nbsp;Eugenia Labaronnie,&nbsp;Patricia M. Zitelli,&nbsp;Alexandre de Araujo,&nbsp;Antonella Olivetti,&nbsp;Daniela Simian,&nbsp;Diego Giunta,&nbsp;Marcelo Silva,&nbsp;Sebastián Marciano","doi":"10.1111/jvh.70035","DOIUrl":"https://doi.org/10.1111/jvh.70035","url":null,"abstract":"<div>\u0000 \u0000 <p>The 2024 WHO guidelines for chronic hepatitis B (CHB) aim to expand and simplify treatment eligibility. We aimed to estimate treatment eligibility and uptake according to country-specific guidelines and evaluate treatment expansion based on the WHO guidelines. Treatment-naïve CHB patients from Argentina, Brazil, Chile and Uruguay referred to evaluation between January 2010 and June 2024 were retrospectively included. Treatment candidacy was evaluated according to both country-specific and WHO guidelines. A total of 719 patients with CHB, treatment naïve, were included (67.1% male; median age: 50.4 years; HBeAg-positive: 36.3%). The median HBV-DNA level was 43,000 (IQR 633–110,000,000) IU/mL, median ALT was 41 (IQR 23–99) U/L, 47.0% had an APRI &gt; 0.5 and 21.1% had cirrhosis. According to country-specific guidelines, 56.9% (95% CI: 53.2–60.5) met the criteria for treatment. Antiviral treatment was initiated in 84.3% of eligible patients. The proportion of patients meeting treatment criteria under the WHO guidelines increased to 67.3% (95% CI: 63.8–70.6), resulting in a 10.4% (95% CI: 8.1–12.8) increase in treatment candidacy. Treatment expansion was significantly higher in women (15.2%; 95% CI: 10.2–20.1) than in men (8.1%; 95% CI: 5.4–10.7). According to WHO guidelines, a considerable proportion of CHB patients who do not meet country-specific criteria are eligible for antiviral therapy. Implementing WHO criteria can enhance treatment rates and advance efforts toward CHB elimination.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 6","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Universal HCV Screening in Hospitalised Patients in France: It Could Be a Good Option! The DEVICHO Study","authors":"Si Ahmed Si Nafa,&nbsp;Souad Benali,&nbsp;Guillaume Penaranda,&nbsp;Sylvie Deuffic-Burban,&nbsp;Magali Madau,&nbsp;Laurence Lecomte,&nbsp;Gaelle Valle,&nbsp;Sandrine Thibault,&nbsp;Constance Chailloux,&nbsp;Valérie Oules,&nbsp;Clara Dassetto,&nbsp;Floriane Sellier,&nbsp;Olivia Pietri,&nbsp;Paul Castellani,&nbsp;Xavier Adhoute,&nbsp;Marc Bourlière","doi":"10.1111/jvh.70038","DOIUrl":"https://doi.org/10.1111/jvh.70038","url":null,"abstract":"<p>In France, chronic hepatitis C whatever fibrosis stage or comorbidities can be freely treated by any physician. However, screening is still currently based on risk factors, and universal screening remains controversial. The aims of this prospective DEVICHO study were to assess the value of universal screening in hospitalised patients, to evaluate the prevalence of HCV infection and to compare the short-term cost and benefit of this strategy with routine screening. From November 2019 to November 2021, all hospitalised patients from 22 departments were asked by their physicians to be tested for HCV. 4986/25,663 (19.4%) in the DEVICHO study (Group 1) and 1803 patients (7%) outside the study (Group 2) were screened. HCV screening rate varied widely (0%–75.1%) between departments. One hundred and ninety-nine patients (2.9%) were HCV-Ab positive. 29/199 HCV-Ab positive patients (14.6%) or 29/6789 patients tested (0.4%) were HCV-RNA positive. Among the 29 viremic patients, 9 (31%) were treated, all achieving sustained virological response, but two patients died rapidly after treatment. Seventeen patients died untreated within a year of diagnosis, and three patients were not treated. Universal screening compared to routine practice would be more expensive and more effective, resulting in an additional cost of €11,060 per HCV RNA infection identified and €36,600 per HCV cure, both below the GDP per capita of France (€38,000, Eurostat 2023). Even if the population screened is older, often with significant comorbidities, hospital-based HCV screening is efficient because its prevalence is higher in hospitalised patients than in the general population. Additionally, this screening strategy appears to be cost effective. However, healthcare professionals and insufficient linkage to care are the main barriers to screening.</p><p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NTC 04437277</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 6","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70038","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144100499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Hepatitis B Patients Referred for Liver Transplantation After Nucleos(t)ide Analog Cessation","authors":"Grishma Hirode,&nbsp;Mai Kilany,&nbsp;Steven Pi,&nbsp;Audrey Kim,&nbsp;Mamatha Bhat,&nbsp;Rafique Van Uum,&nbsp;Leslie B. Lilly,&nbsp;Bettina E. Hansen,&nbsp;Jordan J. Feld,&nbsp;Nazia Selzner,&nbsp;Harry L. A. Janssen","doi":"10.1111/jvh.70031","DOIUrl":"https://doi.org/10.1111/jvh.70031","url":null,"abstract":"<p>Nucleos(t)ide analogs (NAs) provide prolonged viral suppression with favourable clinical outcomes in chronic hepatitis B (CHB) patients. Characterisation of adverse hepatic events after NA cessation leading to liver transplantation (LT) is vital to the improvement of patient management and safety considerations. This is a retrospective case series of CHB patients who developed hepatic decompensation due to NA discontinuation and were referred for LT. Patients with hepatocellular carcinoma or coinfection were excluded. Of 11 CHB patients included (81.8% clinical jaundice, 63.6% ascites, 54.5% hepatic encephalopathy and 18.2% variceal bleeding), 45.5% underwent LT, 36.4% were waitlisted (1 active, 1 died, 2 delisted of whom 1 died), and 18.2% died after referral during the assessment period. Median age was 55.1 years, 81.8% were male, and 72.7% had cirrhosis at NA cessation. Reasons for NA withdrawal included nonadherence (81.8%) and physician discretion (18.2%). Median time from NA cessation to a decompensating event was 3.2 months, and from the decompensating event to referral was 16.0 days. This study shows that most patients experience decompensations soon after NA cessation and reinforces that patients should not discontinue treatment themselves. Physicians should very carefully select non-cirrhotic, adherent patients for NA withdrawal, after which close monitoring and timely retreatment are crucial.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 6","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70031","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143950248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Droplet Digital PCR: A Powerful Tool for Accurate Quantification of Hepatitis D Virus RNA Levels and Verification of Detection Limits","authors":"L. Sandmann,&nbsp;L. Windzio,&nbsp;B. Bremer,&nbsp;S. Falak,&nbsp;J. Beheim-Schwarzbach,&nbsp;A. Kummrow,&nbsp;M. Cornberg,&nbsp;H. Wedemeyer,&nbsp;B. Maasoumy,&nbsp;E. Valiente","doi":"10.1111/jvh.70036","DOIUrl":"https://doi.org/10.1111/jvh.70036","url":null,"abstract":"<p>Reliable quantification of hepatitis D virus (HDV) RNA levels is necessary for initiating and guiding antiviral treatment. The aim of this work is to develop and validate a digital PCR method for the accurate quantification of HDV RNA, including evaluation of its clinical accuracy, especially for low-concentrated clinical samples. The reverse transcription digital PCR (RT-dPCR) development followed the standard procedure, including primer design, determination of linearity, calculation of recovery and the intermediate precision of the RNA extraction kits, determination of the limit of detection (LOD) and quantification (LOQ), droplet size measurements, conversion factor, and uncertainty budget. The World Health Organisation (WHO)-HDV international standard was used for RT-dPCR development. Commutability of the new method was explored, comparing RT-dPCR with quantification assays applied in clinical routine using clinical plasma samples covering a range of HDV RNA concentrations. The conversion factor from copies/mL to IU/mL was 0.77. LOD and LOQ of the RT-dPCR were 0.7 copies/mL (0.56 IU/mL) and 10 copies/mL (8 IU/mL), respectively. When evaluating the qualitative results of the clinical HDV samples at low concentrations, 31% of the HDV clinical samples tested negative by RT-qPCR were tested positive by RT-dPCR. The RT-qPCR and RT-dPCR quantitative data showed a good correlation with a standard deviation of ±1.12 log IU/mL. RT-dPCR is an accurate method for HDV RNA quantification that may serve as a complement to RT-qPCR, especially when accurate detection is essential for decision making in clinical settings.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 6","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143950247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Risk Factors for Hepatocellular Carcinoma in Patients With Delta Hepatitis: A Prognostic Study","authors":"Speranta Iacob,&nbsp;Mirela Chitul,&nbsp;Diana Stan,&nbsp;Daria Gheorghe,&nbsp;Mugur Grasu,&nbsp;Razvan Iacob,&nbsp;Cristian Gheorghe,&nbsp;Irinel Popescu,&nbsp;Liliana Gheorghe","doi":"10.1111/jvh.70034","DOIUrl":"https://doi.org/10.1111/jvh.70034","url":null,"abstract":"<p>Given that delta hepatitis is associated with a 2–6 times higher risk for hepatocellular carcinoma (HCC) compared to HBV monoinfection, we aimed to identify the negative prognostic factors for complications associated with HDV infection (particularly HCC) and to validate BEA score as a screening tool for HCC in HDV. Our retrospective single centre study included all consecutive admissions of adult patients with chronic HDV infection in the period 01.01.2021–31.12.2022. The negative prognostic factors identified were higher MELD (<i>p</i> &lt; 0.0001) and higher BEA score on admission (<i>p</i> &lt; 0.0001), older age on HBV diagnosis (<i>p</i> &lt; 0.0001) and advanced fibrosis when PegINF was administered (<i>p</i> = 0.01). Good prognostic factors were: Class A—BEA score (<i>p</i> = 0.001), normal platelet count (<i>p</i> = 0.00001), normal albumin level (<i>p</i> = 0.001) and prior treatment with PegInf (<i>p</i> = 0.01). ROC curve showed 78.5% sensitivity for BEA score &gt; 2, validating it as a potential screening tool for HCC. Hence, for patients with BEA score &gt; 2 imaging screening should be intensified in order to early diagnose HCC and prompt access to curative treatment. Additionally, the negative prognostic factors identified (MELD &gt; 15, advanced fibrosis when treated with PegINF or diagnosis with HBV infection at an older age) should encourage more frequent monitoring for HCC compared to local guidelines recommendations.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 6","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143939547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Host Factor SRSF7 Promotes HBV Replication Through Binding to and Stabilising Viral pgRNA","authors":"Yu Peng,&nbsp;Yuxin Song,&nbsp;Xin Liu,&nbsp;Xinyu Du,&nbsp;Zhao Zhou,&nbsp;Guangxin Yu,&nbsp;Xiangmei Chen,&nbsp;Fengmin Lu","doi":"10.1111/jvh.70024","DOIUrl":"https://doi.org/10.1111/jvh.70024","url":null,"abstract":"<div>\u0000 \u0000 <p>Hepatitis B virus (HBV) is the primary etiological agent of chronic hepatitis B (CHB) infection, posing a serious threat to human health. The pregenomic RNA (pgRNA) of HBV is the template for HBV reverse transcription, and the epsilon stem-loop (ε) is required for nucleocapsid assembly. The host factor serine/arginine (SR)-rich splicing factor 7 (SRSF7) is a splicing regulator and RNA-binding protein that was involved in regulating viral RNA splicing and export from the nucleus during the viral life cycle, but its biological function and regulatory mechanisms in HBV remain unclear. In this study, SRSF7 was found to promote HBV replication and upregulate HBV RNA levels through knockdown or overexpression of SRSF7 in different cell lines using the HBV replication model. Surprisingly, we found that SRSF7 enhanced HBV RNA stability at the post-transcriptional level, rather than regulating its splicing. We further demonstrated that SRSF7 could bind to pgRNA; deletion of the bulge and loop structures of the ε element significantly reduced its binding capacity. In addition, we confirmed that SRSF7 supports HBV replication in CHB patients. Our study suggests that the host factor SRSF7 promotes HBV replication, which provides new perspectives for further elucidation of HBV-host interactions and the development of host-targeted anti-HBV drugs.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 6","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143919642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Traditional Chinese Medicine External Therapies in Treating Insomnia in Patients With Chronic Hepatitis B: Systematic Review and Meta-Analysis","authors":"Chen Xu,&nbsp;Dong-Hao Yin,&nbsp;Jia-Hao Han,&nbsp;Ya-Nan Gao,&nbsp;Xiu-Hui Li,&nbsp;Xiao-Jun Wang","doi":"10.1111/jvh.70030","DOIUrl":"https://doi.org/10.1111/jvh.70030","url":null,"abstract":"<div>\u0000 \u0000 <p>To systematically evaluate the efficacy of traditional Chinese medicine (TCM) external therapies in treating insomnia in patients with chronic hepatitis B (CHB). PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang, CQVIP and SinoMed were searched for randomised controlled trials (RCTs) on the treatment of insomnia in patients with CHB using TCM external therapies from the establishment of each database until 31 January 2024. A total of six Chinese articles were included, involving 500 patients. The overall response rate of TCM external therapies for CHB combined with insomnia was superior to that of the control group (odds ratio [OR] = 3.08, 95% confidence interval [CI]: [1.86, 5.12], <i>p</i> &lt; 0.001). Additionally, subgroup analysis showed significant effects of acupuncture (OR = 3.51, 95% CI: [1.80, 6.86], <i>p</i> = 0.001) and other external therapies (OR = 2.58, 95% CI: [1.19, 5.62], <i>p</i> = 0.02). Moreover, TCM external therapies substantially improved the Pittsburgh Sleep Quality Index (mean difference [MD] = −2.08, 95% CI: [−2.86, −1.29], <i>p</i> &lt; 0.001) and the Insomnia Severity Index (MD = −3.17, 95% CI: [−4.07, −2.26], <i>p</i> &lt; 0.001). The group using TCM external therapies showed significantly lower SAS scores than the control group (MD = −6.52, 95% CI: [−12.23, −0.82], <i>p</i> = 0.02). One study reported a higher incidence of adverse reactions in the group treated with TCM external therapies than in the control group (<i>p</i> &lt; 0.05). Another study found that the group treated with TCM external therapies had a significantly lower recurrence rate (15.38%) than the control group (35.90%) (<i>p</i> &lt; 0.05). Traditional Chinese medicine external therapies are clinically effective for CHB combined with insomnia, as they can improve sleep quality and relieve insomnia symptoms.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 6","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143919881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological Burden of Hepatitis Delta Virus in the United States","authors":"Elizabeth M. Marlowe,&nbsp;Brooke E. Swanson,&nbsp;Susan E. Realegeno,&nbsp;William A. Meyer III,&nbsp;Robert Gish,&nbsp;Ron M. Kagan","doi":"10.1111/jvh.70029","DOIUrl":"https://doi.org/10.1111/jvh.70029","url":null,"abstract":"<div>\u0000 \u0000 <p>Hepatitis D virus (HDV) affects nearly 5% of people globally who are chronically infected with hepatitis B virus, according to the World Health Organisation. The prevalence of HDV in the United States is considered lower than in other countries. However, HDV seroprevalence studies of the US population are limited, and reported seroprevalences vary. To improve diagnoses, universal HDV testing of hepatitis B surface antigen (HBsAg)-positive specimens has been proposed. The objective of this study was to estimate the prevalence of HDV infection within the United States in HBsAg-positive specimens. Unique deidentified remnant HBsAg-positive specimens submitted for routine clinical testing to Quest Diagnostics, representing all 10 Health and Human Services (HHS) regions, were included. Reflex testing of HBsAg-positive specimens for HDV antibody testing, and further testing of positive specimens for HDV RNA, was conducted from July 2023 to June 2024 for 5251 HBsAg-positive specimens. The cohort was 45% female, with mean ages of 50.8 (M) and 49.4 (F) years. The seroprevalence of anti-HDV was 2.2% [95% CI: 1.8%–2.6%; range: 2.5%–4.1%]. Of 107 anti-HDV-positive specimens, 28% were positive for HDV RNA (viral load range: 94–7,480,000 IU/mL: <i>n</i> = 23; Detected &lt; 40 IU/mL: <i>n</i> = 7). This is the first nationwide seroprevalence study examining HBsAg-positive samples collected from 10 HHS regions across the United States, which offers an overview of the prevalence of HDV in the United States through the use of HbsAg-positive remnant specimens in proportion to regional population sizes. Expanded screening for HDV would help identify patients who may benefit from HDV-related interventions.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 6","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}